---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-25-000026"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:32:28.820539+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics reports positive Phase 2 Advance-HTN trial results for lorundrostat in hypertension

## Summary
- Lorundrostat 50 mg achieved a 7.9 mmHg placebo-adjusted reduction in 24-hour SBP at week 12 (p=0.001).
- 41% of lorundrostat patients achieved 24-hour SBP <125 mmHg at week 4 vs 18% on placebo (p<0.001).
- Trial enrolled 53% Black and 40% female patients; safety showed low discontinuation and confirmed hyperkalemia rates of 2.1% and 3.2%.
- Company plans to provide additional Phase 3 Launch-HTN data at an upcoming medical conference.

## SEC filing metadata
- accession: 0001933414-25-000026
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/0001933414-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/mlys-20250329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-25-000026
- JSON: https://secwatch.observer/filing/0001933414-25-000026.json
- Plain text: https://secwatch.observer/filing/0001933414-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.